Abstract: Certain poly(oxyalkylene) colorants are disclosed along with method of preparation thereof. A method of using these colorants as fluorescent security taggants is also disclosed.

Abstract: Device for collection and stabilization of biomarkers in liquid samples. In at least one embodiment of a fluid collection device, the device comprises a first tube operable to receive a body fluid, a second tube operable to dispense a body fluid, and a suction device operably connected to the second opening of the first tube and the first end of the second tube, wherein the suction device is operable to produce negative pressure through the first tube and is operable to exert positive pressure through the second tube. An embodiment of the devices also comprises a stabilizing agent contained within the fluid collection device, the stabilizing agent capable of completely or substantially preventing the degradation or inactivation of a diagnostic agent in a body fluid upon receipt of the body fluid into the fluid collection device.

Abstract: Sample container for biomarker maintenance. In at least one embodiment of a system for stabilizing a diagnostic marker of the present disclosure, the system comprises a sample container having an opening and least one rigid chamber for containing a body fluid, the body fluid comprising at least one diagnostic marker, a stabilizing agent contained within the sample container, the stabilizing agent capable of completely or substantially preventing the degradation or inactivation of the diagnostic marker, and a securing device for closing the opening of the sample container, wherein the stabilizing agent is coupled to a solid support. In an exemplary embodiment of a system of the present disclosure, the stabilizing agent may be adsorbed to the solid support.

Abstract: Systems and methods for fertility analysis. In at least one embodiment of a system of the present disclosure, the system comprises a stabilizing agent useful to completely or substantially prevent degradation or inactivation of a diagnostic marker for fertility in a body fluid comprising the diagnostic marker, and a detection agent capable of detecting the diagnostic agent. In an exemplary embodiment, the stabilizing agent may be selected from the group consisting of a protease inhibitor, a DNase inhibitor, and a RNase inhibitor.

Abstract: Methods of determining stabilization compounds for predictive biomarkers. According to at least one embodiment of a method of the present disclosure, the method comprises introducing a diagnostic marker and a stabilization agent to a detection platform, mixing the diagnostic marker and stabilization agent, and determining their binding characteristics. Additionally, the method may further comprise generating a report based on the binding characteristics and delivering the report to a recipient.

Abstract: Drink mixture for the stabilization of diagnostic biomarkers. In at least one embodiment of an ingestible beverage useful to stabilize a diagnostic marker, the rinse comprises a stabilizing agent useful to completely or substantially prevent degradation or inactivation of a diagnostic marker in saliva, and a liquid.

Abstract: Systems and Methods for Improving Biomarker Availability.

Abstract: Systems and methods for detecting insulin resistance biomarkers. At least one embodiment of a system of the present disclosure comprises a stabilizing agent useful to completely or substantially prevent degradation or inactivation of a diagnostic marker for insulin resistance or glucose intolerance in a body fluid comprising the diagnostic marker, and a detection agent capable of detecting the diagnostic marker.

Abstract: Systems and methods for determining calcium levels. In at least one embodiment of a system of the present disclosure, the system comprises a stabilizing agent useful to completely or substantially prevent degradation or inactivation of a diagnostic marker for circulating calcium in a body fluid comprising the diagnostic marker, and a detection agent capable of detecting the diagnostic agent.

Abstract: Systems and methods for diagnosing bacterial infections. According to at least one embodiment of a system of the present disclosure, the system a stabilizing agent useful to completely or substantially prevent degradation or inactivation of a diagnostic marker for a bacterial infection in a body fluid comprising the diagnostic marker and a detection agent capable of detecting the diagnostic marker.

Abstract: Chewable compositions for the stabilization of diagnostic biomarkers. In at least one embodiment of a chewing gum composition useful to stabilize a diagnostic marker, the a chewing gum composition comprises a stabilizing agent useful to completely or substantially prevent degradation or inactivation of a diagnostic marker in saliva, and a liquid.

Abstract: Transport container for stabilized liquid samples. In at least one embodiment of a system for the transport of biological samples, the transport system comprises an inner container having at an opening and least one rigid chamber for containing a body fluid comprising at least one diagnostic marker, a stabilizing agent contained within the inner container, the stabilizing agent capable of completely or substantially preventing the degradation or inactivation of a diagnostic agent for at least twenty four hours following interaction with the diagnostic agent, a securing device for closing the opening of the inner container, wherein the stabilizing agent is linked to a solid support, and wherein the inner container is comprised of a material resistant to fracture.

Abstract: Systems and methods for the inhibition of galactose oxidase. According to least one embodiment of a stabilizing system of the present disclosure, the system comprises a stabilizing agent useful to completely or substantially prevent degradation or inactivation of a diagnostic marker by galactose oxidase in a body fluid including the diagnostic marker. The stabilizing system also includes a detection agent capable of detecting the diagnostic marker.

Abstract: Methods of Identifying Biomarkers for Cancer. According to at least one embodiment of a method of identifying diagnostic markers of cancer of the present disclosure, the method comprises the steps of contacting a body fluid of a diseased subject having a cancer with a stabilizing agent capable of completely or substantially preventing the degradation or inactivation of a diagnostic marker, analyzing the stabilized body fluid to determine at last one property of the diagnostic marker to create a cancer profile, comparing the cancer profile with a control profile of a healthy subject not having the cancer, wherein the control profile is created in a like manner to the cancer profile, and generating a cancer identifier panel from the compared cancer profile, wherein the cancer identifier panel contains at least one cancer diagnostic marker indicative of the cancer.

Abstract: Systems and methods of screening biomarkers in bodily fluids. According to at least one embodiment of the system for analyzing stabilizing agents of the present disclosure, the system comprises a detection platform comprising a plurality of detection sites each capable of receiving a diagnostic marker, a stabilization agent, and a detection agent. The system, in at least one embodiment, further comprises a detection device capable of determining a binding characteristic between the detection agent and the diagnostic marker in the detection sites. Further, the system may also be able to compare the binding characteristic among a plurality of detection markers to order the level of effect of the stabilizing agents assayed on the binding characteristic between the detection agent and the diagnostic agent.

Abstract: Systems and methods for hemoglobin analysis. At least one embodiment of a stabilizing system comprises a stabilizing agent useful to completely or substantially prevent degradation or inactivation of a glycosylated hemoglobin (HbA1c) in a body fluid and a detection agent capable of detecting the HbA1c.

Abstract: Systems and methods for diagnosing cancer. According to at least one embodiment of a stabilizing system of the present disclosure, the system comprises a stabilizing agent useful to completely or substantially prevent degradation or inactivation of a diagnostic marker for cancer in a body fluid comprising the diagnostic marker and a detection agent capable of detecting the diagnostic marker.

Abstract: Methods for determining the efficiency of a therapeutic. In at least one embodiment of a method of determining the efficacy of a therapeutic compound, the method comprises the steps of treating a subject having a disease state with an effective amount of therapeutic compound, harvesting at least one cell from the subject following a treatment with the therapeutic compound, bringing the at least one cell into contact with a stabilizing compound capable of completely or substantially preventing the degradation or inactivation of a diagnostic marker for the disease state, analyzing the at least one stabilized cell for the at least one diagnostic marker, creating a marker profile from at least one result determined from analyzing the at least one stabilized cell, and comparing the marker profile with at least one previous marker profile to determine efficacy of the therapeutic compound on the disease state.

Abstract: Biomarker stabilizing agents. In at least one embodiment of a stabilizing bead of the present disclosure, the stabilizing bead comprises a latex particle having a carboxylate group, and a stabilizing agent functionally coupled to the latex particle, wherein the stabilizing agent is capable of completely or substantially preventing the degradation or inactivation of a diagnostic agent in close proximity to the stabilizing agent. Optionally, an embodiment of a stabilizing bead may further comprise at least one of human serum albumin (HSA) and bovine serum albumin (BSA). Moreover, an embodiment of a stabilizing bead of the present disclosure may further comprise a linker group coupled to latex particle.

Abstract: Devices and systems for biomarker detection . In at least one embodiment of a diagnostic testing device of the present disclosure, the device comprises a fluid collector to collect a body fluid, and a housing, to test and retain the body fluid. The housing, in at least one embodiment, comprises a collection chamber, having an open end, to receive the fluid collector and contain a stabilization reagent, at least one membrane test strip, to indicate the presence or absence of at least one diagnostic marker, and an immunoassay-based fingerprint acquisition pad in fluid communication with the collection chamber.